StockNews.AI
NTRB
StockNews.AI
48 days

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

1. Nutriband declares a 25% preferred stock dividend for shareholders. 2. Preferred shares are convertible after FDA approval of AVERSA fentanyl product. 3. Focus on finalizing FDA development pathway for AVERSA commercialization. 4. AVERSA technology aims to prevent misuse of fentanyl and similar drugs. 5. Nutriband holds patents in multiple countries for AVERSA technology.

6m saved
Insight
Article

FAQ

Why Bullish?

Approval of a preferred stock dividend typically indicates financial strength. Historical precedents show that such dividends can enhance shareholder value, signaling confidence in future growth.

How important is it?

The preferred stock dividend and FDA pathways reflect strategic moves. This could attract more investment and positively impact NTRB’s stock performance as commercialization approaches.

Why Short Term?

The dividend announcement and FDA approval process can influence investor sentiment quickly. Immediate interest may arise from the upcoming preferred share issuance and commercialization efforts.

Related Companies

NTRBW
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company’s AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual basis as decided by the board of Directors. "Our core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA fentanyl. We recently highlighted our Commercialization manufacturing process scale up with Kindeva and we are now laser focused on finalizing our development pathway to FDA approval," said Gareth Sheridan, CEO. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband Inc. Phone: 407-377-6695 Email: info@nutriband.com SOURCE: Nutriband Inc.

Related News